Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 4 - Trang 1-10 - 2018
Christine M. Ramsey1, Danijela Gnjidic2, George O. Agogo1, Heather Allore1,3, Daniela Moga4,5,6
1Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
2Faculty of Pharmacy and Charles Perkins Centre, University of Sydney, Camperdown, New South Wales, Australia
3Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA
4Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY, USA
5Department of Epidemiology, University of Kentucky, College of Public Health, Lexington, KY, USA
6University of Kentucky, Sanders-Brown Center on Aging, Lexington, KY, USA

Tóm tắt

AbstractIntroductionPotentially inappropriate medication (PIM) use in older adults with dementia is an understudied area. We assessed longitudinal changes in PIM exposure by dementia type following dementia diagnosis.MethodsWe followed 2448 participants aged ≥65 years (52% women, 85.5% Caucasian, mean age 80.9 ± 7.5 years) diagnosed with dementia after enrollment in the National Alzheimer's Coordinating Center (2005–2014). We estimated the association between dementia type and PIM annually for 2 years after diagnosis, using Generalized Estimating Equations.ResultsParticipants with Lewy body dementia had more PIM use, and participants with frontotemporal dementia had less PIM use than participants with Alzheimer's disease. In the first year following diagnosis, total number of medications increased, on average, by 10% for Alzheimer's disease and 15% for Lewy body dementia (P < .05 for both).DiscussionA tailored approach aimed at optimizing drug therapy is needed to mitigate PIM exposure to improve medical care for individuals with dementia.

Tài liệu tham khảo

Clague F., 2017, Comorbidity and polypharmacy in people with dementia: insights from a large, population‐based cross‐sectional analysis of primary care data, Age Ageing, 46, 33 10.1001/jama.293.11.1348 10.3928/0098-9134-20050901-04 10.1186/1471-2318-11-58 10.1007/BF03324775 10.1056/NEJMsb042458 10.1111/j.1532-5415.2010.03032.x 10.1007/s00228-007-0422-1 Bell J.S., 2012, Anticholinergic and sedative medicines ‐ prescribing considerations for people with dementia, Aust Fam Physician, 41, 45 10.2174/157488471003150820150330 10.2174/1574884710666150609154741 10.1001/jama.283.24.3230 10.1111/jgs.13702 10.1177/0091270006292126 10.1001/jamainternmed.2014.7663 10.3233/JAD-160581 10.1177/0091270010395591 10.1177/2042098615613984 10.1345/aph.19006 10.1097/WAD.0b013e31819d6ec9 10.1592/phco.2005.25.6.831 10.1001/archinte.165.1.68 10.1001/archinternmed.2009.229 10.2165/00023210-200216120-00003 10.1016/j.jamda.2013.03.014 10.1111/j.1447-0594.2011.00800.x 10.1371/journal.pone.0169463 10.1001/jamainternmed.2014.4103 10.1177/2042098616670798 10.1017/S1041610298005262 10.1212/WNL.47.5.1148 10.1001/archneur.1987.00520160031010 10.1212/WNL.46.1.130 10.4140/TCP.n.2006.563 10.1111/j.1532-5415.2004.52563.x 10.1097/WAD.0b013e318142774e 10.1097/01.wad.0000213865.09806.92 10.1097/WAD.0b013e318191c7dd Beekly D.L., 2004, The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database, Alzheimer Dis Assoc Disord, 18, 270 10.1016/S0022-510X(97)00289-X 10.1136/jnnp.73.4.390 10.1097/NEN.0b013e31824b211b 10.1212/WNL.41.4.479 10.1212/WNL.34.7.939 10.1212/WNL.43.11.2412-a 10.1016/0022-3956(82)90033-4 10.1111/j.1532-5415.2005.53461.x 2013, Base SAS® 94 10.1016/S0929-6646(09)60150-9
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 4

1-10

Thông tin tác giả